In 2023, nearly 1 in 4 US adults were living with chronic pain, and 8.5% experienced pain severe enough to limit daily life ...

The listening room with a bespoke sound system reflecting Alessandro Michele's vision was conceived in partnership with ...

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their research efforts around the adeno-associated virus (AAV) vectors used ...

Some insurers limit sessions to just 20 a year. They also often pause coverage to require re-authorization of physical ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...

Shares of Vertex Pharmaceuticals ( VRTX -12.76%) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came ...

The clinical pause is “temporary” and applies to a multiple ascending dose portion of a trial assessing VX-522, a Moderna-partnered mRNA therapy, according to Vertex’s May 5 earnings release.

EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U ...

From a new product perspective, Vertex is progressing nicely with Casgevy (a gene therapy treatment for sickle cell disease) securing authorized treatment centers worldwide, including key ...

The deal has been announced just a few days after the FDA lifted a clinical hold on a phase 1/2 trial of VX-880 – a stem cell therapy Vertex acquired through its near $1 billion acquisition of ...

Cheng Xin / Getty Images Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped. The biotech firm also posted a decline in sales outside the U.S. because of ...